This exclusive webinar is based on Arlington Medical Resources’ recently launched European Anticoagulant Market Guide.
Date & Time
Wednesday, December 15, 2010
9 a.m. ET, 3 p.m. CET
This webinar, presented by Arlington Medical Resources’ Director Matthew Mahr, Pharm.D., M.B.A., will answer the following questions:
- What is the inpatient versus outpatient opportunity for anticoagulants given after hip and knee replacement surgery? What is the distribution of patients by duration of hospital stay after surgery? What agents are patients discharged with?
- What is the current prevalence of anticoagulant bridging? Are patients receiving Arixtra, low molecular weight heparins, or even vitamin K antagonists? How frequently do patients receive both an injectable and an oral anticoagulant for thromboprophylaxis after hip or knee replacement surgery?
- Are prescribers in Europe using bridging with Xarelto or Pradaxa and how does this compare to what is done with traditional oral anticoagulants?
- If apixaban and edoxaban are approved for indications such as stroke prevention in atrial fibrillation, is there a potential for cost savings due the decreased need for bridging?
This webinar was held on December 20, 2010. Contact us to learn how you can access the recorded event.
Click here to view the invite.